Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

CatalYm: opening up tumors to immune cells

Emerging Company Profile: German start-up targets GDF15’s immunosuppressant function to enable immune cell infiltration to tumors

By stephen hansen, Associate Editor
November 11, 2020 12:15 AM UTC

CatalYm is targeting a lesser known immunosuppressant function of GDF15 to resensitize cancer patients to checkpoint blockade and enhance the ability of CAR T therapies to infiltrate solid tumors.

The Munich-based biotech has raised €50 million ($58.2 million) in a series B round led by Vesalius Biocapital III to bring lead program CTL-002 into a large Phase I trial to treat multiple solid tumors...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Catalym GmbH